VCM
BBNX

Versant Capital Management’s Beta Bionics BBNX Stock Holding History

Versant Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.18K Buy
458
+159
+53% +$1.89K ﹤0.01% 2341
2026
Q1 		$3K Sell
299
-844
-74% -$12.5K ﹤0.01% 2495
2025
Q4 		$34.8K Hold
1,143
– – ﹤0.01% 1296
2025
Q3 		$22.7K Buy
1,143
+271
+31% +$4.76K ﹤0.01% 1521
2025
Q2 		$12.7K Buy
+872
New +$12.3K ﹤0.01% 1779

Other funds holding BBNX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
IWM
Iams Wealth Management Omaha, Nebraska $332M AUM 18.77% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Versant Capital Management's BBNX Position: Q2 2026 in Review

Versant Capital Management increased its Beta Bionics (BBNX) stake by 53% in Q2 2026, buying an estimated $1.89K and bringing the position to 458 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Versant Capital Management first reported a position in BBNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $34.8K in Q4 2025. 18 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Versant Capital Management held 458 shares of Beta Bionics worth $7.18K as of Q2 2026.
  • Versant Capital Management bought 159 Beta Bionics shares in Q2 2026, an estimated $1.89K.
  • Beta Bionics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2341 holding.
  • Versant Capital Management first reported a position in Beta Bionics in Q2 2025 and has held it in 5 quarters since.
  • Versant Capital Management's Beta Bionics position peaked at $34.8K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.